Could GLP-1s become part of addiction treatment in the future
With approximately 25 million projected GLP-1 users by 2030 up from roughly 11 million in 2025 and the behavioral evidence showing consistent, durable changes in eating patterns, the brands that adapt their packaging, portions, and nutritional profiles now will build a competitive advantage that compounds over time
Getting the dose right matters: too little may do nothing, while more than needed wastes product without clearly improving results
The companies were basically mass producing copycat medications, says Mansoor Amiji, distinguished professor of pharmaceutical sciences and chemical engineering at Northeastern
Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, et al